Skip to main content

Klein Joseph III's Form 4 filing

Ionis Pharmaceuticals Inc (IONS) · filed Jul 19, 2022

Accession no.
0000874015-22-000140
Filed
Jul 19, 2022
Trade date
Jul 15, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $51.0K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Klein Joseph IIICIK 0001206369Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jul 15, 2022Common StockMOption exerciseAcquired+5,333$0.00$017,459Direct
Jul 15, 2022Common StockMOption exerciseAcquired+2,665$0.00$020,124Direct
Jul 15, 2022Common StockSSaleDisposed−689$37.74F4−$26,002.8619,435Direct
Jul 15, 2022Common StockSSaleDisposed−644$38.78F5−$24,974.3218,791Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jul 15, 2022Common StockMOption exerciseDisposed−5,333$0.00$09,775Direct
Jul 15, 2022Common StockMOption exerciseDisposed−2,665$0.00$07,110Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F4

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.26 to $38.225 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

Referenced by the price of 1 transaction in Table I.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.44 to $39.23 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (5) on this Form 4.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)